Review of the Latest Therapeutic Approaches in the Management of Irritable Bowel Syndrome
DOI:
https://doi.org/10.12775/QS.2025.39.58919Keywords
ibs, irritable bowel syndrome, gut microbiota, abdominal pain, constipation, diarrhea, rifaximin, neuromodulatorsAbstract
Irritable bowel syndrome (IBS) is a common and chronic bowel disease which, although it does not lead to severe and permanent complications, significantly deteriorates patients' quality of life. It constitutes a considerable psychological burden for them and also represents a significant socio-economic problem for the healthcare system.
Although the cause of the disease is complex and still not fully understood, the update of the Rome criteria has led to significant progress in understanding the pathophysiology of the disease and researching alternative treatment methods. As a result, modern therapeutic approaches can be better tailored to the predominant symptoms and individual needs of the patient.
This review compiles the latest research findings on the etiopathogenesis of the disease and discusses available therapeutic strategies, including options unavailable in Poland. This enables a better selection of effective therapy and achievement of satisfactory treatment outcomes through a more individualized approach, tailored to the patient's specific clinical profile.
References
1. Pietrzak A, Skrzydło-Radomańska B, Mulak A et al. Guidelines on the management of irritable bowel syndrome. Gastroenterology Review/Przegląd Gastroenterologiczny. 2018;13(4):259-288. doi:10.5114/pg.2018.78343. Polish.
2. Adrych K. Irritable Bowel Syndrome in Light of the Latest Guidelines. Varia Medica. 2019;3(2):89-95. Polish
3. Barbara G, Feinle-Bisset C, Ghoshal UC, Quigley EM et al. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016 Feb 18:S0016-5085(16)00219-5. doi: 10.1053/j.gastro.2016.02.028. PMID: 27144620.
4. Wei W, Wang H, Zhang Y, Zhang Y et al. Faecal bile acids and colonic bile acid membrane receptor correlate with symptom severity of diarrhoea-predominant irritable bowel syndrome: A pilot study. Dig Liver Dis. 2021 Sep;53(9):1120-1127. doi: 10.1016/j.dld.2021.04.022. PMID: 34053874.
5. Algera JP, Colomier E, Melchior C, Hreinsson JP et al. Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome. Neurogastroenterol Motil. 2023 Feb;35(2):e14482. doi: 10.1111/nmo.14482. PMID: 36221245.
6. Grinsvall C, Ryu HJ, Van Oudenhove L, Labus JS et al. Association between pain sensitivity and gray matter properties in the sensorimotor network in women with irritable bowel syndrome. Neurogastroenterol Motil. 2021 Apr;33(4):e14027. doi: 10.1111/nmo.14027. PMID: 33174312.
7. Huang KY, Wang FY, Lv M, Ma XX et al. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol. 2023 Jul 14;29(26):4120-4135. doi: 10.3748/wjg.v29.i26.4120. PMID: 37475846.
8. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. PMID: 22730468.
9. Mangell P, Nejdfors P, Wang M, Ahrné S et al. Lactobacillus plantarum 299v inhibits Escherichia coli-induced intestinal permeability. Dig Dis Sci. 2002 Mar;47(3):511-6. doi: 10.1023/a:1017947531536. PMID: 11911334.
10. Dinan TG, Cryan JF. Gut-brain axis in 2016: Brain-gut-microbiota axis - mood, metabolism and behaviour. Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):69-70. doi: 10.1038/nrgastro.2016.200. PMID: 28053341.
11. Wiercińska M, Bartnik W. Irritable bowel syndrome (IBS) - symptoms, diet, treatment. Medycyna Praktyczna. Available from: https://www.mp.pl/pacjent/gastrologia/choroby/jelitogrube/80662,zespol-jelita-drazliwego-jelito-drazliwe-ibs-objawy-dieta-leczenie. Accessed February 11, 2025. Polish.
12. Jiang H, Ling Z, Zhang Y, Mao H et al. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav Immun. 2015 Aug;48:186-94. doi: 10.1016/j.bbi.2015.03.016. PMID: 25882912.
13. Rukavishnikov G, Leonova L, Kasyanov E et al. Antimicrobial activity of antidepressants on normal gut microbiota: Results of the in vitro study. Front Behav Neurosci. 2023 Mar 22;17:1132127. doi: 10.3389/fnbeh.2023.1132127. PMID: 37035624.
14. Hanna-Jairala I, Drossman DA. Central Neuromodulators in Irritable Bowel Syndrome: Why, How, and When. Am J Gastroenterol. 2024 Jul 1;119(7):1272-1284. doi: 10.14309/ajg.0000000000002800. PMID: 38595149.
15. Qin HY, Cheng CW, Tang XD, Bian ZX. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014 Oct 21;20(39):14126-31. doi: 10.3748/wjg.v20.i39.14126. PMID: 25339801.
16. Wnęk D. FODMAP Diet – The Recommended Diet for Irritable Bowel Syndrome. Medycyna Praktyczna. Available from: https://www.mp.pl/pacjent/dieta/diety/diety_w_chorobach/111607,dieta-fodmap-dieta-zalecana-w-zespole-jelita-drazliwego. Accessed February 11, 2025. Polish.
17. Allescher HD, Burgell R, Malfertheiner P, Mearin F. Multi-target Treatment for Irritable Bowel Syndrome with STW 5: Pharmacological Modes of Action. J Gastrointestin Liver Dis. 2020 Jun 3;29(2):227-233. doi: 10.15403/jgld-814. PMID: 32530990.
18. Alam MS, Roy PK, Miah AR, Mollick SH et al. Efficacy of Peppermint oil in diarrhea predominant IBS - a double blind randomized placebo - controlled study. Mymensingh Med J. 2013 Jan;22(1):27-30. PMID: 23416804.
19. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012 Aug 14;18(30):4012-8. doi: 10.3748/wjg.v18.i30.4012. PMID: 22912552.
20. Rai RR, Dwivedi M, Kumar N. Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: a randomized double-blind placebo-controlled study. Saudi J Gastroenterol. 2014 Nov-Dec;20(6):378-82. doi: 10.4103/1319-3767.145331. PMID: 25434320.
21. Schäfer E, Ewe K. The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon. Fortschr Med. 1990 Aug 30;108(25):488-92. PMID: 2210587. German.
22. Lembo A, Pimentel M, Rao SS, Schoenfeld P et al. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology. 2016 Dec;151(6):1113-1121. doi: 10.1053/j.gastro.2016.08.003. PMID: 27528177.
23. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. PMID: 22045120.
24. Drossman DA, Tack J, Ford AC, Szigethy E et al. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report. Gastroenterology. 2018 Mar;154(4):1140-1171.e1. doi: 10.1053/j.gastro.2017.11.279. PMID: 29274869.
25. Fadgyas Stanculete M, Dumitrascu DL, Drossman D. Neuromodulators in the Brain-Gut Axis: their Role in the Therapy of the Irritable Bowel Syndrome. J Gastrointestin Liver Dis. 2021 Nov 23;30(4):517-525. doi: 10.15403/jgld-4090. PMID: 34812436.
26. Depoortère R, Meleine M, Bardin L et al. Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents. Eur J Pharmacol. 2011 Dec 15;672(1-3):83-7. doi: 10.1016/j.ejphar.2011.09.182. PMID: 21996314.
27. Peng LH, Fang JY, Dai N, Shen XZ et al. Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial. J Dig Dis. 2022 Feb;23(2):99-110. doi: 10.1111/1751-2980.13081. PMID: 35019221.
28. Cash BD, Sharma A, Walker A, Laitman AP, Chang L. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation. Neurogastroenterol Motil. 2023 Sep;35(9):e14632. doi: 10.1111/nmo.14632. PMID: 37332239.
29. Drossman DA, Chey WD, Johanson JF, Fass R et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009 Feb 1;29(3):329-41. doi: 10.1111/j.1365-2036.2008.03881.x. PMID: 19006537.
30. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59. doi: 10.1046/j.1365-2036.1999.00610.x. PMID: 10468696.
31. Bonetto S, Fagoonee S, Battaglia E et al. Recent advances in the treatment of irritable bowel syndrome. Pol Arch Intern Med. 2021 Aug 30;131(7-8):709-715. doi: 10.20452/pamw.16067. PMID: 34463082.
32. Liu R, Staller K. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives. Drug Des Devel Ther. 2020 Apr 9;14:1391-1400. doi: 10.2147/DDDT.S216056. PMID: 32308371.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Martyna Mrozek, Małgorzata Blecharczyk, Paweł Jakubiec, Maciej Kosiński, Alicja Nowik, Martyna Pacanowska, Marcin Sękulski, Igor Zydlewski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 306
Number of citations: 0
